Both projects and programs are opportunities for direct member involvement to help benefit the biopharmaceutical manufacturing community, but they have some key complementary differences.
As of June 30, 2024
We achieve our mission through an RFx process that aims to advance technical and workforce development projects:
NIIMBL is organizing a special session at this year’s National Meeting, scheduled for June 23-25, 2026. Last year’s Innovation Tank session received overwhelmingly positive feedback and engagement, and we are excited to continue the format again this year.
This Request for Information (RFI) invites interested parties to self-nominate for participation in the Innovation Tank, a special pitch targeted to find the most promising technologies that directly address issues in biopharma manufacturing.
The session will feature a “Shark Tank”-style pitch event, where up to three organizations will be invited to pitch their promising biopharmaceutical manufacturing-related technology to a panel of experts.
Each selected organization will be given 20 to 30 minutes to deliver a 5-to 7-minute pitch about your technology followed by panel question and answer. The winning technology pitch will be determined by the panel with audience poll results weighted into the decision.
NIIMBL is organizing a special workforce session at this year’s National Meeting, scheduled for June 23-25, 2026.
This Request for Information (RFI) invites interested and eligible parties to self-nominate for participation in a special “Shark Tank” like session at the National Meeting, with an outcome of identifying the most promising new and emerging non-degree workforce program that directly addresses the challenges of building the biopharma manufacturing pipeline.
This interactive session will kick off with a brief overview of the Impact Assessment Framework, equipping the audience with the lenses through which program impact is measured by NIIMBL. Then, up to three organizations will take the stage to pitch their most innovative and impactful workforce programs. Each organization will have 20 to 30 minutes to deliver a 5–7-minute pitch and respond to questions from a panel of experts representing industry, academia, and government.
Following the pitches, both the audience and the expert panel will vote to determine which program demonstrates the greatest potential for advancing the biopharmaceutical workforce.
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
Objectives
Requirements
Project Call 9.1 is now closed.
NIIMBL is pleased to announce Project Call 9.1, with member- driven and industry-led priority topic areas for technical development proposals.
Technology Topics:
Workforce Development Topics
RFI: Technology Innovation Tank
NIIMBL is organizing a special session at this year’s National Meeting, scheduled for June 23-25, 2026. Last year’s Innovation Tank session received overwhelmingly positive feedback and engagement, and we are excited to continue the format again this year.
This Request for Information (RFI) invites interested parties to self-nominate for participation in the Innovation Tank, a special pitch targeted to find the most promising technologies that directly address issues in biopharma manufacturing.
The session will feature a “Shark Tank”-style pitch event, where up to three organizations will be invited to pitch their promising biopharmaceutical manufacturing-related technology to a panel of experts.
Each selected organization will be given 20 to 30 minutes to deliver a 5-to 7-minute pitch about your technology followed by panel question and answer. The winning technology pitch will be determined by the panel with audience poll results weighted into the decision.
RFI: Workforce Innovation Tank
NIIMBL is organizing a special workforce session at this year’s National Meeting, scheduled for June 23-25, 2026.
This Request for Information (RFI) invites interested and eligible parties to self-nominate for participation in a special “Shark Tank” like session at the National Meeting, with an outcome of identifying the most promising new and emerging non-degree workforce program that directly addresses the challenges of building the biopharma manufacturing pipeline.
This interactive session will kick off with a brief overview of the Impact Assessment Framework, equipping the audience with the lenses through which program impact is measured by NIIMBL. Then, up to three organizations will take the stage to pitch their most innovative and impactful workforce programs. Each organization will have 20 to 30 minutes to deliver a 5–7-minute pitch and respond to questions from a panel of experts representing industry, academia, and government.
Following the pitches, both the audience and the expert panel will vote to determine which program demonstrates the greatest potential for advancing the biopharmaceutical workforce.
RFA: Faculty Fellows
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
Objectives
Requirements
RFP: Project Call 9.1
Project Call 9.1 is now closed.
NIIMBL is pleased to announce Project Call 9.1, with member- driven and industry-led priority topic areas for technical development proposals.
Technology Topics:
Workforce Development Topics
NIIMBL funded 32 coronavirus response projects to multiple organizations across the United States.
NIIMBL awarded 11 new member-led technology, workforce development, and Global Health Fund projects with a value of ~$11.2 million.
December 2023
LigaTrap Technologies, LLC, Merck & Co., Inc., MilliporeSigma/EMD Serono, North Carolina State University, Rensselaer Polytechnic Institute
August 2023
North Carolina State University
August 2023
PATH Center for Vaccines Innovation & Access
August 2023
Fraunhofer USA
November 2022
Merck & Co., Inc., Pfizer, Inc., University of Maryland Baltimore
Mission
Accelerate the development and adoption of data-driven innovation and standards to increase the speed and resilience of biopharmaceutical manufacturing.
Vision
Data-driven technologies optimize the productivity of biopharmaceutical manufacturing and accelerate the delivery of high-quality medicines to patients.
By 2029, the PI program proposes to invent, design, demonstrate, and support commercialization of integrated biopharmaceutical manufacturing technology to transform drug substance (DS) and drug product (DP) manufacturing capability, enabling the following:
Mission
Accelerate the implementation of new preventive medical countermeasure manufacturing technologies across multiple platform processes by addressing workforce and technology issues that U.S. and global manufacturers and suppliers face and establishing a Center of Excellence for Vaccine Analytics and Assays.
Vision
Accelerate the production of innovative preventive medical countermeasures by ensuring that both U.S.-based and global medical countermeasure manufacturers and suppliers have adequate support to implement advanced manufacturing and product characterization processes.
Learn more about the Preventive Medical Countermeasure Program
Mission
Develop and make broadly available a robust, economically viable, shared-access platform for the technical development, manufacturing, and characterization of AAV-based gene therapy vectors. Ensure that workforce training for this platform can integrate into existing curriculum or training models to encourage adoption, and integrate improvements into the platform based on feedback from these training programs.
Vision
A gene-based therapeutics industry capable of serving patients across the full spectrum of unmet needs—from prevalent indications to ultra-rare diseases—that has access to high-quality viral vectors without cost or speed limitations.
Big data
Mission
Accelerate the development and adoption of data-driven innovation and standards to increase the speed and resilience of biopharmaceutical manufacturing.
Vision
Data-driven technologies optimize the productivity of biopharmaceutical manufacturing and accelerate the delivery of high-quality medicines to patients.
Process intensification
By 2029, the PI program proposes to invent, design, demonstrate, and support commercialization of integrated biopharmaceutical manufacturing technology to transform drug substance (DS) and drug product (DP) manufacturing capability, enabling the following:
Preventive Medical Countermeasures
Mission
Accelerate the implementation of new preventive medical countermeasure manufacturing technologies across multiple platform processes by addressing workforce and technology issues that U.S. and global manufacturers and suppliers face and establishing a Center of Excellence for Vaccine Analytics and Assays.
Vision
Accelerate the production of innovative preventive medical countermeasures by ensuring that both U.S.-based and global medical countermeasure manufacturers and suppliers have adequate support to implement advanced manufacturing and product characterization processes.
Learn more about the Preventive Medical Countermeasure Program
Viral vector manufacturing & analytics
Mission
Develop and make broadly available a robust, economically viable, shared-access platform for the technical development, manufacturing, and characterization of AAV-based gene therapy vectors. Ensure that workforce training for this platform can integrate into existing curriculum or training models to encourage adoption, and integrate improvements into the platform based on feedback from these training programs.
Vision
A gene-based therapeutics industry capable of serving patients across the full spectrum of unmet needs—from prevalent indications to ultra-rare diseases—that has access to high-quality viral vectors without cost or speed limitations.
The NIIMBL eXperience is a hands-on, expenses-paid week-long program for college first years and sophomores to gain real-world insight into career possibilities in biopharmaceutical manufacturing.
It’s also an opportunity for NIIMBL academic or non-profit Member organizations to serve as regional lead organizations that will plan, recruit students, and run a NIIMBL eXperience program in their region.
The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member or at NIIMBL’s Headquarters in Delaware to support NIIMBL-led projects.
We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.